flumazenil has been researched along with propranolol in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (13.04) | 18.7374 |
| 1990's | 4 (17.39) | 18.2507 |
| 2000's | 6 (26.09) | 29.6817 |
| 2010's | 10 (43.48) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Barber, J; Dawson, S; Kenna, JG; Paul, N; Stahl, S | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Hashimoto, S; Kasahara, K; Nagatani, T; Takao, K | 1 |
| Elgoyhen, AB; Kazanietz, MG | 1 |
| Baldwin, HA; File, SE | 1 |
| Cole, BJ; Koob, GF | 1 |
| Doare, L; Puech, AJ; Simon, P; Thiebot, MH | 1 |
| Kawaguchi, M; Okubo, M | 1 |
| Kitraki, E; Philippidis, H; Stylianopoulou, F; Tritos, N | 1 |
| Kunitake, T; Shirasaka, T; Tsuneyoshi, I | 1 |
1 review(s) available for flumazenil and propranolol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
22 other study(ies) available for flumazenil and propranolol
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Cholestasis; Drug-Related Side Effects and Adverse Reactions; Humans; Insecta; Rats; Risk Factors | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Role of the central serotonergic system in the anticonflict effect of d-AP159.
Topics: 5,7-Dihydroxytryptamine; Amygdala; Animals; Anti-Anxiety Agents; Buspirone; Chromatography, High Pressure Liquid; Conflict, Psychological; Electrochemistry; Flumazenil; Male; Microinjections; Propranolol; Pyridines; Rats; Rats, Wistar; Serotonin; Stereoisomerism; Thienopyridines | 1992 |
Relaxant effect of benzodiazepines on uterine rings isolated from estrogen-treated rats.
Topics: Animals; Anti-Anxiety Agents; Benzodiazepinones; Bicuculline; Clonazepam; Convulsants; Diazepam; Estradiol; Estrogens; Female; Flumazenil; In Vitro Techniques; Isoquinolines; Muscle, Smooth; Potassium Chloride; Propranolol; Rats; Rats, Inbred Strains; Uterine Contraction | 1990 |
Caffeine-induced anxiogenesis: the role of adenosine, benzodiazepine and noradrenergic receptors.
Topics: 2-Chloroadenosine; Adenosine; Alprazolam; Anxiety; Caffeine; Chlordiazepoxide; Clonidine; Flumazenil; Motor Activity; Muscle Relaxants, Central; Norepinephrine; Propranolol; Receptors, Adrenergic; Receptors, GABA-A; Receptors, Purinergic; Social Behavior | 1989 |
Propranolol antagonizes the enhanced conditioned fear produced by corticotropin releasing factor.
Topics: Animals; Anxiety; Carbolines; Conditioning, Psychological; Corticotropin-Releasing Hormone; Fear; Flumazenil; Locus Coeruleus; Male; Motor Activity; Propranolol; Rats; Receptors, Adrenergic, beta; Receptors, Serotonin; Stereoisomerism | 1988 |
U 43,465F: a benzodiazepine with antidepressant activity? Interaction with Ro 15-1788 and d,1-propranolol.
Topics: Alprazolam; Animals; Anti-Anxiety Agents; Antidepressive Agents; Apomorphine; Benzodiazepines; Benzodiazepinones; Body Temperature; Drug Interactions; Flumazenil; Male; Mice; Propranolol | 1982 |
Inhibitory regulation of amylase release in rat parotid acinar cells by benzodiazepine receptors.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Amylases; Animals; Atropine; Benzodiazepinones; Carbachol; Clonazepam; Diazepam; Dose-Response Relationship, Drug; Flumazenil; GABA Modulators; GABA-A Receptor Agonists; GABA-A Receptor Antagonists; Isoproterenol; Male; Muscarinic Agonists; Muscarinic Antagonists; Parotid Gland; Propranolol; Rats; Rats, Wistar; Receptors, GABA-A | 1998 |
Neurotransmitter modulation of glucocorticoid receptor mRNA levels in the rat hippocampus.
Topics: Adrenergic beta-Antagonists; Animals; Blotting, Northern; Diazepam; Dizocilpine Maleate; Down-Regulation; Excitatory Amino Acid Antagonists; Flumazenil; GABA Modulators; Hippocampus; Injections, Intraperitoneal; Male; Neurotransmitter Agents; Propranolol; Rats; Rats, Wistar; Receptors, Glucocorticoid; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; Stress, Psychological | 1999 |
Cardiovascular responses to intravenous injection of a novel isoindolin-1-one derivate in conscious rats.
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Animals; Atropine; Baroreflex; Blood Pressure; Catecholamines; Catheters, Indwelling; Dose-Response Relationship, Drug; Flumazenil; GABA Modulators; Heart Conduction System; Heart Rate; Isoindoles; Male; Naloxone; Narcotic Antagonists; Parasympatholytics; Piperazines; Propranolol; Rats; Rats, Wistar; Sinoatrial Node; Sympathetic Nervous System; Time Factors | 2009 |